HARBIN, China, April 21 China Sky OneMedical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), aleading fully integrated pharmaceutical company producing over-the-counterdrugs in the People's Republic of China ("PRC"), today announced it hadcommenced the commercial launch of Oxymetazoline Hydrochloride Nasal Drops andMoschus Liniment for Pain Relief.
Oxymetazoline Hydrochloride Nasal Drops, a generic drug, is to treat acuteand chronic rhinitis, sinusitis and allergic rhinitis. Moschus Liniment forPain Relief is a TCM product developed in-house, which is used to relieve thepain from scathe, wound, rheumatism and arthrosis.
The two products, quite reliable and convenient for consumers' use, areestimated to have a market size of over $300 million each. The Company willanalyze and summarize the marketing and sales activities following the trialstage and establish a formal sales plan soon.
"We are happy to add two new products to our sales mix and anticipate theywill contribute roughly $1.0 million to our total revenues in 2010," said Mr.Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We continue ourefforts to commercialize 11 additional drugs in our R&D pipeline in order tosupport sustainable, long term growth."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio-Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin ChuangPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward-looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include the commercial launch of OxymetazolineHydrochloride Nasal Drops and Moschus Liniment for Pain Relief. Actual resultscould differ materially from the expectations reflected in suchforward-looking statements as a result of a variety of factors, including therisks associated with the ability to launch new products, market acceptance ofnew product launches, the effect of changing economic conditions in ThePeople's Republic of China, variations in new product development, risksassociated with rapid technological change, and the potential of introduced orundetected flaws and defects in products, and other risk factors detailed inreports filed with the Securities and Exchange Commission from time to time.For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-451-8703-2617 Email: [email protected]
Investor Relations Contact: CCG Investor Relations Ms. Lei Huang, Account Manager Tel: +1-646-833-3417 Email: [email protected]
Web: http://www.ccgirasia.com Ms. Mabel Zhang, Vice President Tel: +1-310-954-1353 Email: [email protected]
SOURCE China Sky One Medical, Inc.